KR101016593B1 - 환식 반아세탈 유도체 및 이의 용도 - Google Patents

환식 반아세탈 유도체 및 이의 용도 Download PDF

Info

Publication number
KR101016593B1
KR101016593B1 KR1020047014523A KR20047014523A KR101016593B1 KR 101016593 B1 KR101016593 B1 KR 101016593B1 KR 1020047014523 A KR1020047014523 A KR 1020047014523A KR 20047014523 A KR20047014523 A KR 20047014523A KR 101016593 B1 KR101016593 B1 KR 101016593B1
Authority
KR
South Korea
Prior art keywords
compound
linear
carbon atoms
alkyl group
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047014523A
Other languages
English (en)
Korean (ko)
Other versions
KR20050006130A (ko
Inventor
마사유끼 나까무라
준 이노우에
Original Assignee
센주 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센주 세이야꾸 가부시키가이샤 filed Critical 센주 세이야꾸 가부시키가이샤
Publication of KR20050006130A publication Critical patent/KR20050006130A/ko
Application granted granted Critical
Publication of KR101016593B1 publication Critical patent/KR101016593B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/22—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Liquid Crystal Substances (AREA)
KR1020047014523A 2002-03-15 2003-03-14 환식 반아세탈 유도체 및 이의 용도 Expired - Fee Related KR101016593B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002072762 2002-03-15
JPJP-P-2002-00072762 2002-03-15
PCT/JP2003/003122 WO2003078415A1 (en) 2002-03-15 2003-03-14 Cyclic hemiacetal derivative and use thereof

Publications (2)

Publication Number Publication Date
KR20050006130A KR20050006130A (ko) 2005-01-15
KR101016593B1 true KR101016593B1 (ko) 2011-02-22

Family

ID=28035193

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047014523A Expired - Fee Related KR101016593B1 (ko) 2002-03-15 2003-03-14 환식 반아세탈 유도체 및 이의 용도

Country Status (10)

Country Link
US (1) US7202274B2 (enExample)
EP (1) EP1489076B1 (enExample)
JP (2) JPWO2003078415A1 (enExample)
KR (1) KR101016593B1 (enExample)
CN (1) CN1297548C (enExample)
AT (1) ATE404548T1 (enExample)
AU (1) AU2003220928A1 (enExample)
DE (1) DE60322856D1 (enExample)
ES (1) ES2307915T3 (enExample)
WO (1) WO2003078415A1 (enExample)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
HUT71250A (en) 1992-05-20 1995-11-28 Senju Pharma Co Remedy for cataract and production thereof
JP2825172B2 (ja) 1992-07-10 1998-11-18 東京エレクトロン株式会社 減圧処理装置および減圧処理方法
JPH08104685A (ja) * 1993-09-03 1996-04-23 Takeda Chem Ind Ltd ラクトール誘導体、その製造法および用途
NO943210L (no) * 1993-09-03 1995-03-06 Takeda Chemical Industries Ltd Laktolderivater, deres fremstilling og anvendelse
US5498616A (en) * 1994-11-04 1996-03-12 Cephalon, Inc. Cysteine protease and serine protease inhibitors
TW394764B (en) * 1995-02-14 2000-06-21 Mitsubishi Chemcal Corp Oxygen-containing heterocyclic derivatives
JPH09169752A (ja) 1995-02-14 1997-06-30 Mitsubishi Chem Corp 含酸素複素環誘導体
DE69625575T2 (de) * 1995-10-25 2003-09-25 Senju Pharmaceutical Co., Ltd. Angiogense-Inhibitor
WO1998004539A1 (en) * 1996-07-29 1998-02-05 Mitsubishi Chemical Corporation Oxygenic heterocyclic derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Current Eye Research, Vol.10, pp.657-666, 1994
The Biochemical Journal, Vol.253, pp.751-758, 1988

Also Published As

Publication number Publication date
CN1297548C (zh) 2007-01-31
CN1642933A (zh) 2005-07-20
ES2307915T3 (es) 2008-12-01
EP1489076B1 (en) 2008-08-13
ATE404548T1 (de) 2008-08-15
JPWO2003078415A1 (ja) 2005-07-14
EP1489076A4 (en) 2005-12-21
KR20050006130A (ko) 2005-01-15
US20050119499A1 (en) 2005-06-02
US7202274B2 (en) 2007-04-10
EP1489076A1 (en) 2004-12-22
JP2010189424A (ja) 2010-09-02
WO2003078415A1 (en) 2003-09-25
DE60322856D1 (enExample) 2008-09-25
AU2003220928A1 (en) 2003-09-29

Similar Documents

Publication Publication Date Title
JP5767307B2 (ja) 虚血および虚血・再灌流障害を治療するための組成物および方法
CN110396085B (zh) 联合治疗
TW201402537A (zh) 犬尿胺酸－３－單氧化酶抑制劑，其醫藥組成物及使用方法
EP2163548A1 (en) Prophylactic or therapeutic agent for age-related macular degeneration
EP2555776B1 (en) Combination compositions of adenosine a1 agonists and non-selective beta-adrenergic receptor blockers for reducing intraocular pressure
EP0842165B1 (en) Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
EP2555775B1 (en) Combination compositions of adenosine a1 agonists and carbonic anhydrase inhibitors for reducing intraocular pressure
KR101016593B1 (ko) 환식 반아세탈 유도체 및 이의 용도
US20050282769A1 (en) Inhibitors of adenosine kinase for the treatment of optic nerve and retinal damage
KR20160113720A (ko) 황 함유 모이어티를 포함하는 당 유도체 및 이의 제조 방법 및 mps iiic의 치료를 위한 이의 사용 방법
JPWO2005061492A1 (ja) 含窒素複素環化合物およびそれらを有効成分とする薬剤
JP4549851B2 (ja) 新規α−ケトアミド誘導体およびその用途
US20110224200A1 (en) Therapeutic agent for chorioretinal degenerative disease containing pyridine-3-carbaldehyde 0-(piperidin-1-yl-propyl)-oxime derivative as active ingredient
KR101032006B1 (ko) 히드록시모르폴리논 유도체 및 이의 의약 용도
HK1073654A (en) Cyclic hemiacetal derivative and use thereof
CH677610A5 (enExample)
EP0750906A1 (en) Delta-(s-methylisothioureido)-l-norvaline and cerebrovascular disorder remedy having nitrogen monoxide synthase inhibitor activity
AU713581C (en) Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents
JP2004043330A (ja) 新規ピリジン誘導体およびその用途
JPWO2002048096A1 (ja) ヒドラゾン誘導体およびその医薬用途
JP2013010695A (ja) 角結膜障害の治療又は予防剤
JPWO2001010442A1 (ja) ジヒドロピリジン化合物を含有する網膜神経節細胞死抑制剤
WO1992015296A1 (en) Remedy for renal diseases

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140216

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140216

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000